DOCS
Doximity, Inc.
DOCS's fundamentals are mixed: it turned 44% of its revenue into free cash flow, but its operating margin fell 13 points to 26%. At 47x earnings, it's trading in line with its usual 50x. Analysts expect earnings to hold roughly steady.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DOCS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Unavailable | |
| Strong |
DOCS's profitability and balance sheet are currently healthy, and its revenue is stable. There isn't enough data to rate its cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DOCS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $33.20 | — |
| Cheap | 35x | $24.67 | -26% |
| Current | 47x | $33.20 | — |
| Fair | 49x | $35.12 | +5.8% |
| Expensive | 63x | $45.04 | +36% |
Historical ranges are pointers, not guarantees.
DOCS's PE is in its fair range at 47x. On analysts' estimates for next year's earnings, today's price would be 23x, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DOCS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Weakening | |
| Moderate | |
| Moderate |
Analysts expect DOCS's revenue to grow, but its profitability to weaken.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DOCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.44 | +103% |
| Q3 2026 | $0.71 | -44% |
| Q2 2026 | $0.84 | -28% |
| Q1 2026 | $0.98 | -12% |
| Q4 2025 | $1.20 | +20% |
| Q3 2025 | $1.26 | +45% |
| Q2 2025 | $1.17 | +46% |
| Q1 2025 | $1.11 | +54% |
| Q4 2024 | $1.00 | +49% |
DOCS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DOCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $174.5M | +3.6% |
| Q2 2026 | $156.6M | +7.3% |
| Q1 2026 | $145.4M | +5.1% |
| Q4 2025 | $185.1M | +9.8% |
| Q3 2025 | $168.5M | +23% |
| Q2 2025 | $145.9M | +15% |
| Q1 2025 | $138.3M | +17% |
| Q4 2024 | $168.6M | +25% |
DOCS's revenue has grown year over year every quarter since late 2020: $175M last quarter, up 3.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | -13 points |
| Q2 2026 | 21% | -16 points |
| Q1 2026 | 17% | -18 points |
| Q4 2025 | 39% | -8.5 points |
| Q3 2025 | 38% | -1.1 points |
| Q2 2025 | 37% | +1 points |
| Q1 2025 | 35% | -0.3 points |
| Q4 2024 | 47% | +4.1 points |
DOCS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DOCS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DOCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $93.3M | -0.7% |
| Q2 2026 | $41.9M | -32% |
| Q4 2025 | $60.9M | -6.6% |
| Q3 2025 | $93.9M | +37% |
| Q2 2025 | $62.1M | +51% |
| Q1 2025 | $98.5M | +54% |
| Q4 2024 | $65.2M | +30% |
| Q3 2024 | $68.3M | +432% |
DOCS has the stronger cash trend. Its trailing FCF is up 65% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
DOCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -3.4M shares |
| 1 year | -6.4% | -12.9M shares |
| 3 years | -10% | -21.2M shares |
| 5 years | -13% | -28.9M shares |
| Available history | +3.4% | +6.1M shares |
DOCS has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $54.2M |
| Q2 2026 | $91.6M |
| Q1 2026 | $90.5M |
| Q4 2025 | $196.9M |
| Q3 2025 | $21.9M |
| Q2 2025 | $122.4M |
| Q1 2025 | $26.8M |
| Q4 2024 | $19.3M |
DOCS spent $433M buying back its own shares over the past year, up 128% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DOCS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -1.3x | Net Cash |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.7x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
DOCS has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DOCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.2 | Neutral |
| Stochastic | 69.8 | Neutral |
DOCS's weekly RSI is 64 (neutral) and its Stochastic is 70 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DOCS PE vs Healthcare Sector
| Metric | DOCS | Sector median | Relative |
|---|---|---|---|
| PE | 47x | 26x | 81% above |
| PE % | 45 | 37 | 8 pts above |
DOCS is trading at 47x earnings, a 81% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DOCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.0 | 7.3% above |
| 20 week MA | $26.8 | 24% above |
| 50 week MA | $28.1 | 18% above |
| 100 week MA | $44.7 | 26% below |
| 200 week MA | $38.1 | 13% below |
DOCS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DOCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $56.0 | $51.5 | -7.9% |
| 2022 | $51.5 | $34.2 | -34% |
| 2023 | $34.2 | $28.0 | -18% |
| 2024 | $28.0 | $57.8 | +106% |
| 2025 | $57.8 | $43.7 | -24% |
| 2026 YTD | $43.7 | $33.2 | -24% |
DOCS has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.